Krsnaa Diagnostics Limited (KRSNAA) Fair Value & Analysis
Healthcare · IN · Market cap ₹18.6B
Fair value as of: Aug 13, 2026
From 16 valuation models · updated 4 days ago
Share price +3.4% over the past month.
Below-average quality, currently priced close to our fair value.
What matters now
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Our model range runs from ₹423.68 (bear) to ₹741.82 (bull), base ₹582.75. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 42/100 (below-average quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ₹356.58 – ₹1,017 · fair‑value band ₹423.68 – ₹741.82 · the ₹558.45 price screens below the ₹582.75 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Krsnaa Diagnostics Limited (KRSNAA) currently trades at ₹558.45, while our model-based Fair Value estimate is ₹582.75, implying the stock looks roughly 4.4% fairly valued today. The Quality Score stands at 42/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Krsnaa Diagnostics Limited generated revenue of ₹8.0B at a net margin of 12.7%. Revenue grew 3.5% year over year. It earns a return on equity of 10.9%. Net debt stands at ₹1.7B. Fundamentals as of Aug 13, 2026
Our scenario range runs from ₹423.68 (bear case) to ₹741.82 (bull case); at ₹558.45, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 38% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -50% fair-value upside, at 4%, KRSNAA screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 16 models by family
Widest divergence: Growth Earnings (₹886.47) versus Dividend Discount (₹44.27). Highest evidence: Residual Income (76).
Notify me when KRSNAA reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 43 · Market factors (momentum, volatility) 36
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Krsnaa Diagnostics Limited provides diagnostic services in India. It offers a range radiology services, including computed tomography scans, magnetic resonance imaging, X-rays, and ultrasound and advanced imaging; pathology services, such as laboratory, and home collection and preventive health; and teleradiology and telepathology services.
Full company description
Krsnaa Diagnostics Limited provides diagnostic services in India. It offers a range radiology services, including computed tomography scans, magnetic resonance imaging, X-rays, and ultrasound and advanced imaging; pathology services, such as laboratory, and home collection and preventive health; and teleradiology and telepathology services. The company also provides other diagnostics services, such as ophthalmic test, mammography, dental imaging, stress test, dual-energy X-ray absorptiometry scan, and bone mineral density test. It serves individual patients, government clients, corporate clients, hospitals, clinics, private practitioner, and other healthcare providers. Krsnaa Diagnostics Limited was incorporated in 2010 and is based in Pune, India.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2026 · reported fiscal years
Krsnaa Diagnostics Limited reported revenue of ₹7.7B in FY2026 versus ₹4.6B in FY2022, a compound +14.1%/yr. Reported net income was ₹1.0B in FY2026, compounding +10.4%/yr from FY2022.
Watch KRSNAA: get an alert when its fair value changes →
Peer Group
Diagnostics & Research · 136 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $603.01 | $308.19 | -49% |
| Danaher Corporation DHR | $205.79 | $103.88 | -50% |
| WuXi AppTec Co 2359 | HK$198.90 | HK$157.39 | -21% |
| Lonza Group LONN | CHF 566.20 | CHF 259.80 | -54% |
| IDEXX Laboratories, Inc IDXX | $570.58 | $255.77 | -55% |
| Agilent Technologies, Inc A | $148.24 | $61.53 | -58% |
| Waters Corporation WAT | $416.15 | $121.96 | -71% |
| IQVIA Holdings IQV | $236.66 | $132.17 | -44% |
| Illumina, Inc ILMN | $192.91 | $95.51 | -50% |
| Mettler-Toledo International Inc MTD | $1,419 | $615.78 | -57% |
Compare Krsnaa Diagnostics Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Krsnaa Diagnostics Limited (KRSNAA) overvalued or undervalued?
What is the fair value of KRSNAA?
What is the quality score of KRSNAA?
What is the revenue of Krsnaa Diagnostics Limited (KRSNAA)?
What is the net profit margin of KRSNAA?
Does Krsnaa Diagnostics Limited pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Krsnaa Diagnostics Limited and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.